Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
2.
J Pediatr Hematol Oncol ; 46(4): 211-215, 2024 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-38573000

RESUMEN

Diffuse intrinsic pontine gliomas are lethal tumors with a prognosis generally less than 1 year. Few cases of survivors of 5 years or more have been reported. This case report highlights the journey of a 9.5-year survivor who underwent 3 rounds of focal radiotherapy; she experienced 6 years of progression-free survival following the first round but ultimately succumbed to her disease. An autopsy revealed a favorable IDH1 mutation and the absence of H3K27M. This case reiterates the importance of extensive molecular analyses in diffuse intrinsic pontine gliomas and explores the potential benefit of re-irradiation in patients with positive responses and long periods of remission.


Asunto(s)
Neoplasias del Tronco Encefálico , Glioma Pontino Intrínseco Difuso , Humanos , Femenino , Neoplasias del Tronco Encefálico/patología , Neoplasias del Tronco Encefálico/terapia , Neoplasias del Tronco Encefálico/mortalidad , Glioma Pontino Intrínseco Difuso/patología , Glioma Pontino Intrínseco Difuso/terapia , Glioma Pontino Intrínseco Difuso/genética , Niño , Supervivencia , Supervivientes de Cáncer , Resultado Fatal , Isocitrato Deshidrogenasa/genética , Pronóstico , Mutación
3.
Childs Nerv Syst ; 40(6): 1965-1969, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38478067

RESUMEN

Pediatric intracranial sarcomas are rare, aggressive tumors with a poor prognosis in general. Here we report the case of a child who was initially diagnosed with a primary intracranial sarcoma, DICER1-mutant; subsequent genetic analyses confirmed a pathogenic germline DICER1 mutation. She received multimodal standard treatments consisting of surgery, radiotherapy and chemotherapy. The tumor recurred 2.5 years later within the surgical cavity. Following the gross tumor resection of this new lesion, the same multimodal standard approach was used. From a molecular perspective, evidence of hyperactivation of the MAPK-kinase pathway with a pathogenic KRAS mutation at both diagnosis and recurrence was present. The patient is currently in remission, 18 months post-end of treatment.


Asunto(s)
Neoplasias Encefálicas , ARN Helicasas DEAD-box , Recurrencia Local de Neoplasia , Ribonucleasa III , Sarcoma , Humanos , Ribonucleasa III/genética , ARN Helicasas DEAD-box/genética , Femenino , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/diagnóstico por imagen , Recurrencia Local de Neoplasia/genética , Sarcoma/genética , Mutación/genética , Niño
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA